The notices it replaced
- Reissues: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 2 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 3 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-17-303.
Who won it before
758 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $239,556,000 in first-year total cost, median $225,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 SBIB-T (10)]52
- Special Emphasis Panel[ZRG1 OTC-T (10)]48
- Special Emphasis Panel[ZRG1 ETTN-G (12)]35
- Special Emphasis Panel[ZRG1 RPHB-C (10)]33
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC7
- MEDOSOME BIOTEC, LLC7
- MICROBIOTIX, INC6
- CORTICOMETRICS, LLC5
- FIREBIRD BIOMOLECULAR SCIENCES, LLC5
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Testing a male oral contraceptive targeting Eppin2R42HD084077-02 | ORAND, MICHAEL GENE | EPPIN PHARMA, INC., NC | $1,097,562 | ZRG1 |
| 2018 | Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes2R42HL127901-02A1 | BETT, GLENNA C L | CYTOCYBERNETICS, INC., NY | $748,969 | ZRG1 |
| 2018 | Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing2R42ES026908-02 | GEORGE, JAYROSENTHAL, DEANSYKORA, PETER | AMELIA TECHNOLOGIES, LLC, DC | $666,400 | ZRG1 |
| 2018 | Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation2R42AI108016-02A1 | DOMEN, ADRIANUS G.W.PANUGANTI, SWAPNA | CELLERANT THERAPEUTICS, INC., CA | $573,592 | ZRG1 |
| 2018 | A software tool for objective identification of concussion-related vision disorders using a novel eye-tracking device1R41NS103698-01A1 | MASTER, CHRISTINA L. | OCULOGICA, INC., NY | $503,162 | ZRG1 |
| 2018 | Nucleobase aminosugars with reduced ototoxicity1R41DC016257-01A1 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $305,919 | ZRG1 |
| 2018 | Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections1R41AI136072-01 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $300,000 | ZRG1 |
| 2018 | Discovery of Zika virus therapeutics using a replicon assay1R41AI136126-01 | BOWLIN, TERRY L. | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2018 | Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO1001R41CA217551-01A1 | CHEN, THOMAS C.WANG , WEIJUN | NEONC TECHNOLOGIES, INC., CA | $300,000 | ZRG1 |
| 2018 | Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae1R41AI136233-01 | FELDMAN, MARIO | VAXNEWMO, LLC, MO | $299,999 | ZRG1 |
| 2018 | Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML1R41CA224830-01 | FRETT, BRENDAN ANDREWGUZMAN, MONICA LLI, HONG YU | SYNACTIX PHARMACEUTICALS, INC., AZ | $299,975 | ZRG1 |
| 2018 | Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence1R41DA044898-01 | BRENNEMAN, DOUGLAS ERICWARD, SARA J | KANNALIFE SCIENCES, INC., NY | $299,916 | ZRG1 |
| 2018 | Quantifying NETosis via Automated High Content Imaging Convolutional Neural Networks1R41AI131840-01A1 | ELSHERIF, LAILA | EPICYPHER, INC., NC | $299,751 | ZRG1 |
| 2018 | Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)1R41EY028839-01 | COOK, JASON | NANOHYBRIDS, INC., TX | $297,786 | ZRG1 |
| 2018 | Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury1R41HL135945-01A1 | BOGATCHEVA, NATALIACLAUSS, MATTHIAS | ALLINAIRE THERAPEUTICS, LLC, OH | $281,155 | ZRG1 |
| 2018 | A cell-free, high-throughput screening service for accelerated GPCR ligand discovery1R41GM126674-01 | SONDEK, JOHN E | KXT, BIO INC., NC | $276,339 | ZRG1 |
| 2018 | Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury1R42NS105238-01 | HUETTEMANN, MAIKSANDERSON, THOMAS HUDSON | MITOVATION, INC., MI | $248,042 | ZRG1 |
| 2018 | Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors1R41DA045398-01 | VASSOLER, FAIR M | WEINBERG MEDICAL PHYSICS, LLC, MD | $229,701 | ZRG1 |
| 2018 | MRI-compatible and integrated devices for simultaneous neural recording, stimulation, imaging1R41NS105298-01 | IRAZOQUI, PEDRO | MR-LINK, LLC, IN | $228,325 | ZRG1 |
| 2018 | Retinal eye-tracking for the prognosis and monitoring of multiple sclerosis1R41NS100222-01A1 | SHEEHY, CHRISTY KATHLEEN | C. LIGHT TECHNOLOGIES, INC., CA | $225,392 | ZRG1 |
| 2018 | Intravascular molecular-structural NIRF-IVUS imaging of coronary artery disease1R41HL140671-01 | JAFFER, FAROUC AMIN | INTRAVASCULAR IMAGING, INC., MA | $225,000 | ZRG1 |
| 2018 | Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics1R41AI131823-01A1 | POLEJAEVA, IRINA A.SULLIVAN, EDDIE J | SAB CAPRA, LLC, UT | $225,000 | ZRG1 |
| 2018 | Embryonic stem cell high throughput screen accurately reports toxic stress1R41ES028991-01 | ABDULHASAN, MOHAMMEDRAPPOLEE, DANIEL ALLEN | REPRODUCTIVE STRESS; MEASUREMENT, MECHANISMS AND MANAGEMENT, CORPORATION, MI | $225,000 | ZRG1 |
| 2018 | Enzymatic attachment of proteins to fluorescent nanodiamond surfaces.1R41GM126603-01 | RAMPERSAUD, ARFAANWOOD, DAVID W | COLUMBUS NANOWORKS, INC., OH | $225,000 | ZRG1 |
| 2018 | Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth1R41HD094622-01 | DAMSKER, JESSE | REVERAGEN BIOPHARMA, INC., MD | $224,998 | ZRG1 |
| 2018 | A universal eye drop adherence monitor to measure and improve adherence to ocular medications1R41EY028807-01 | MANSBERGER, STEVEN LPORTER, JOSE D | UNIVERSAL ADHERENCE, LLC, OR | $224,997 | ZRG1 |
| 2018 | TFEB Activator for Alzheimer’s Disease Therapy1R41AG058364-01 | LI, YANGMEI | BRILLIANT BIOSCIENCES, INC., FL | $224,997 | ZRG1 |
| 2018 | Innovative TME-specific Pro-CAR T-cells for Immunotherapy of Solid Tumors1R41CA224652-01 | HUANGPU, JUN | PANACISE BIO, INC., NC | $224,991 | ZRG1 |
| 2018 | Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS1R41HL140741-01 | GARCIA, JOE G. N. | RESTORE THERAPEUTICS, LLC, AZ | $224,984 | ZRG1 |
| 2018 | Oxidation-resistant Anti-protease Therapy1R42HL140670-01 | CRYSTAL, RONALD G | LEXEO THERAPEUTICS, LLC, NY | $224,967 | ZRG1 |
| 2018 | Interventions to Improve Reproductive Health among Adolescents1R41HD094406-01 | CHINMAN, MATTHEWFIRPO-TRIPLETT, REGINA | DFUSION, INC., CA | $224,957 | ZRG1 |
| 2018 | Reopening the Central Airway With Needle-Size Tentacle Manipulators1R41HL140709-01 | WEBSTER, ROBERT JAMES | VIRTUOSO SURGICAL, INC., TN | $224,598 | ZRG1 |
| 2018 | 3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)1R41HL139290-01A1 | WEST, KARL | CENTERLINE BIOMEDICAL, INC., OH | $223,868 | ZRG1 |
| 2018 | MtLDL detection to diagnose childhood tuberculosis1R41AI136071-01 | SAMPSON, NICOLE S | CHRONUS PHARMACEUTICALS, INC., NY | $223,406 | ZRG1 |
| 2018 | staRt: Enhancing speech treatment with smartphone-delivered biofeedback1R41DC016778-01 | MCALLISTER, TARA | GIRLFRIENDS LABS, LLC, NY | $222,939 | ZRG1 |
| 2018 | Reprogrammed T Cells to prevent graft versus host disease1R41AI136755-01A1 | BELLUCCI, JOSEPH J | ELEMENT GENOMICS, INC., NC | $221,507 | ZRG1 |
| 2018 | Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease1R42AG058333-01 | SOTO, CLAUDIOVOLLRATH, BEN | AMPRION, INC., CA | $217,647 | ZRG1 |
| 2018 | An Engineered Nanoimmunotherapy for Melanoma1R41CA217294-01A1 | FERNANDES, ROHANSWEENEY, ELIZABETH EVILLAGRA, ALEJANDRO V | IMMUNOBLUE, LLC, MD | $200,001 | ZRG1 |
| 2018 | Commercialization of a Rapid Blood Test for Traumatic Brain Injury1R41NS102118-01A1 | LOVELL, MARK ANTHONY | FAWKES BIOTECHNOLOGY, LLC, KY | $197,824 | ZRG1 |
| 2018 | The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy1R41DA044894-01A1 | TOLL, LAWRENCE R | PHOENIX PHARMALABS, INC., UT | $186,687 | ZRG1 |
| 2018 | Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture1R41AI136225-01 | NAJJAR, AMER MTSENG, HUBERT | NANO3D BIOSCIENCES, INC., TX | $175,849 | ZRG1 |
| 2018 | Inter-examiner Agreement of a Novel Device for the Measurement of Cervical Dilation in Labor: A Randomized Controlled Trial1R41HD094398-01 | BERGHELLA, VINCENZO | ELM TREE MEDICAL INC., CA | $168,683 | ZRG1 |
| 2018 | Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users1R41DA044788-01 | KEWEKORDES, JOSEFSHAO, XUESI MAX | AUTOMATE SCIENTIFIC, INC., CA | $150,000 | ZRG1 |
| 2017 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF25232R42CA192656-02A1 | MORALES, GUILLERMO A | SIGNALRX PHARMACEUTICALS, INC., GA | $1,320,558 | ZRG1 |
| 2017 | An Accessible Digital Intervention to Promote HIV Testing/Counseling and Prevention Among Adolescents2R42HD088317-02 | FIELLIN, LYNN ELIZABETHSCHELL, JESSE | SCHELL GAMES, LLC, PA | $1,100,650 | ZRG1 |
| 2017 | Peripheral FAAH as a target for novel analgesics2R42DA033683-02A1 · under PA-14-072 | PIOMELLI, DANIELE | ANTEANA THERAPEUTICS, INC., CA | $1,100,244 | ZRG1 |
| 2017 | Urine Diagnostics for Aspergillosis2R42AI115866-02A1 | MARR, KIEREN A. | PEARL DIAGNOSTICS, INC., MD | $1,004,193 | ZRG1 |
| 2017 | Validation of Novel Therapeutic Approach for Cryptococcal Meningitis2R42AI120304-02 · under PA-15-270 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $1,000,000 | ZRG1 |
| 2017 | Peripheral Nerve-on-a-chip for Predictive Preclinical Pharmaceutical Testing2R42TR001270-02 | CURLEY, JABE LMOORE, MICHAEL J | AXOSIM, INC., LA | $963,541 | ZRG1 |
| 2017 | Aspirin-PC for Chemoprevention of Colorectal Cancer2R42CA171408-02A1 | LICHTENBERGER, LENARD M | PLX OPCO, INC., TX | $961,499 | ZRG1 |
| 2017 | Albumin Nanoparticles Incorporating Piceatannol (PANPs) for ALI/ARDS therapy2R42HL126456-03A1 | KANTETI, PRASAD V. S.MALIK, ASRAR B. | CELL BIOLOGICS, INC., IL | $959,212 | ZRG1 |
| 2017 | Interactive technology for media literacy drug prevention in community groups2R42DA039595-02A1 | GREENE, KATHRYN LHECHT, MICHAEL | REAL PREVENTION, LLC, NJ | $873,000 | ZRG1 |
| 2017 | Design and Development of Immunotolerant S. aureus Biotherapies2R42AI118133-02 · under PA-15-270 | BAILEY-KELLOGG, CHRISGRISWOLD, KARL E | LYTICON, LLC, NH | $868,526 | ZRG1 |
| 2017 | Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease2R42AI122403-02 | AMAN, M JAVADLAI, JONATHAN R. | INTEGRATED BIOTHERAPEUTICS, INC., MD | $861,259 | ZRG1 |
| 2017 | Development of user-friendly fluorescence based assays for marine toxins2R42ES023724-02A1 · under PA-15-270 | MCCALL, JENNIFER RETTEW | SEATOX RESEARCH, INC., NC | $854,503 | ZRG1 |
| 2017 | Lactoferrin Modulation of Granuloma Pathology2R42AI117990-02 · under PA-15-270 | ACTOR, JEFFREY KKRUZEL, MARIAN L | PHARMAREVIEW CORPORATION, TX | $815,321 | ZRG1 |
| 2017 | CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells2R42AI126905-02 | ALLBRITTON, NANCY L.ARMISTEAD, PAUL MICHAEL | CELL MICROSYSTEMS, INC., NC | $801,389 | ZRG1 |
| 2017 | Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery2R42CA192504-02 · under PA-15-270 | SHEKHAR, RAJ | IGI TECHNOLOGIES, INC., MD | $774,136 | ZRG1 |
| 2017 | AutoRegister: A system for enhancing the accuracy of tumor change detection2R42CA183150-02 · under PA-15-270 | VAN DER KOUWE, ANDRE JAN WILLEMWIGHTON, PAUL | CORTICOMETRICS, LLC, MA | $750,000 | ZRG1 |
| 2017 | Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment2R42DE025789-02 | EBETINO, FRANK H.SEDGHIZADEH, PARISH PAYMON | BIOVINC, LLC, CA | $750,000 | ZRG1 |
| 2017 | Restimulating memory T cell responses in elderly by a novel, live influenza vaccine2R42AI120269-02 | BILSEL, PAMUKIWASAKI, AKIKO | FLUGEN, INC., WI | $746,327 | ZRG1 |
| 2017 | Improvements to Biopharmaceutical Manufacturing2R42GM114935-02 | SHARFSTEIN, SUSAN T | HOCUSLOCUS, INC., NY | $733,711 | ZRG1 |
| 2017 | Microfluidic Nitric Oxide Sensor2R42AI112064-03 | CAIRNS, BRUCE AMCDUNN, JONATHAN EDWARD | CLINICAL SENSORS, INC., NC | $723,682 | ZRG1 |
| 2017 | An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care2R42HD087021-02A1 | KASSAM-ADAMS, NANCYMCLAUGHLIN, JEFFERY | RADIANT CREATIVE GROUP, LLC, TX | $715,833 | ZRG1 |
| 2017 | Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects2R42AI122574-02 | VANDENBARK, ARTHUR A. | VIROGENOMICS BIODEVELOPMENT, INC., OR | $702,706 | ZRG1 |
| 2017 | Tissue Engineered Intestine2R42DK107168-02 | BESNER, GAIL EJOHNSON, JED KIZER | NANOFIBER SOLUTIONS, LLC, OH | $694,464 | ZRG1 |
| 2017 | Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis2R42CA183376-02 | YANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $602,227 | ZRG1 |
| 2017 | Small Molecule Therapy for the Treatment of Heart Failure1R42HL132684-01A1 | HAJJAR, ROGER J. | SUMOCOR, LLC, NJ | $550,612 | ZRG1 |
| 2017 | Nutritional Therapy in Elderly with Heart Failure2R42AG050375-02 | WOLFE, ROBERT R | ESSENTIAL BLENDS, LLC, AK | $544,749 | ZRG1 |
| 2017 | Science Take-Out Kits for Environmental Health Education2R42ES023706-02 | HOLT, SUSANMARKOWITZ, DINA GROSSMAN | SCIENCE TAKE-OUT, LLC, NY | $524,883 | ZRG1 |
| 2017 | Advanced Assessment to Accelerate Diagnostic Skill Acquisition, Phase II2R42GM108104-02A1 | CIANCIOLO, ANNALAVOIE, NOELLE | PARALLEL CONSULTING, LLC, CA | $500,000 | ZRG1 |
| 2017 | Augmenting Dual Energy CT for Novel Contrast Agents2R42DK104580-02A1 | YEH, BENJAMIN M | NEXTRAST, INC., CA | $499,999 | ZRG1 |
| 2017 | Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets2R42GM115130-02 | BENNER, STEVEN AYANG, ZUNYI | FIREBIRD BIOMOLECULAR SCIENCES, LLC, FL | $499,573 | ZRG1 |
| 2017 | Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine2R42GM116622-02 | MORRISON, DAN | 490 BIOTECH, INC., TN | $496,198 | ZRG1 |
| 2017 | Development of Pirenzepine for HIV-SN1R41NS105177-01 | FIELDS, JEREL ADAMMIZISIN, ANDREW | WINSANTOR, INC., CA | $466,421 | ZRG1 |
| 2017 | Numerical Tools for Predicting Drug Dissolution Profiles2R42GM090513-02A1 | PARK, TAESHIN | RES GROUP, INC., MA | $450,920 | ZRG1 |
| 2017 | Development of a Clinical Screening Platform for Type 1 Diabetes1R42DK115296-01 | WAGNER, DAVID H. | OP-T-MUNE, INC., CO | $421,182 | ZRG1 |
| 2017 | Novel Treatment for Traumatic Brain Injury1R41NS098903-01A1 | TUCCI, FABIO COHENUTESHEV, VICTOR V | EPIGEN BIOSCIENCES, INC., CA | $417,267 | ZRG1 |
| 2017 | ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute1R42HL135965-01A1 | DOCTOR, ALLAN | KALOCYTE, INC., MD | $397,622 | ZRG1 |
| 2017 | Development of PAR4 Pepducins as a Novel Antithrombotic Treatment1R41HL134517-01A1 · under PA-15-270 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $366,484 | ZRG1 |
| 2017 | Anti-CCL25 mAb to treat castration resistant prostate cancer1R41CA214080-01 · under PA-15-270 | SINGH, SHAILESH | JYANT, INC., GA | $350,000 | ZRG1 |
| 2017 | A Novel Probiotic Platform to Treat Necrotizing Enterocolitis1R41GM122130-01A1 | BESNER, GAIL EGOODMAN, STEVEN D | MONON BIOVENTURES, LLC, IN | $331,395 | ZRG1 |
| 2017 | A novel approach to treat non-alcoholic steatohepatitis (NASH)1R41DK112429-01A1 | RINCON, MERCEDES | MITOTHERAPEUTIX, LLC, CT | $317,953 | ZRG1 |
| 2017 | Methamphetamine vaccine for Humans1R42DA043311-01A1 | KOGAN, YAKOVKOSTEN, THOMAS | KADVAX TECHNOLOGIES, INC., TX | $305,976 | ZRG1 |
| 2017 | HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension1R42HL132742-01A1 | YU, PAUL B | VASCULAR BIOSCIENCES, CA | $302,402 | ZRG1 |
| 2017 | Vastly improved influenza diagnostics through the development of a handheld thermal contrast reader1R41NR017825-01A1 | BISCHOF, JOHN C | VIGILANT DIAGNOSTICS, LLC, MN | $300,939 | ZRG1 |
| 2017 | Identification of Small Molecule Amyloid Beta Peptide Reducing Agent1R41AG058517-01 | NEFZI, ADEL | SMART BIOMOLECULES, INC., FL | $300,001 | ZRG1 |
| 2017 | Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy1R41CA213463-01 · under PA-15-270 | SZABO, CSABA | CBS THERAPEUTICS, INC., TX | $300,000 | ZRG1 |
| 2017 | Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure1R41HL134435-01A1 | JORNS, MARILYN S | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,000 | ZRG1 |
| 2017 | Development of Zika viral pseudoinfectious virus as Zika vaccine candidate1R41AI129119-01A1 | PANG, XIAOWUZHOU, YANFEI | TENGEN BIOMEDICAL CO., MD | $300,000 | ZRG1 |
| 2017 | Therapeutic antibodies for treatment of hantavirus cardiopulmonary syndrome1R41AI132047-01 | BOTTEN, JASON W.FANGER, MICHAEL W | CELDARA MEDICAL, LLC, NH | $300,000 | ZRG1 |
| 2017 | Robust Predictor of Breast Cancer Risk1R41CA217383-01A1 | OSTRER, HARRY | MORGAN AND MENDEL GENOMICS, INC., DE | $300,000 | ZRG1 |
| 2017 | Polyionic Papillomavirus-like Particles (VLP) for the Treatment of HPV+ oropharyngeal squamous cell carcinomas (OPCs)1R41CA224469-01 | WANG, JOSHUA WEIYUAN | PATHOVAX, LLC, MD | $300,000 | ZRG1 |
| 2017 | DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS1R41EY026849-01A1 · under PA-15-270 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $299,999 | ZRG1 |
| 2017 | Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates1R41CA210857-01A1 | KHANNA, RAJESH | REGULONIX, LLC, NY | $299,999 | ZRG1 |
| 2017 | Development, Characterization & Commercialization of a Viably Frozen, Patient-Inclusive Hepatocellular Carcinoma Tumor Bank1R41CA213678-01A1 | BRIGGS, MICHAELDUDA, DAN GABRIEL | WOODLAND PHARMACEUTICALS, LLC, MA | $299,999 | ZRG1 |
| 2017 | Caveolae-Targeted Cisplatin Immunoconjugates for Effective Lung Cancer Therapy1R41CA217399-01A1 | LEVIN, MICHAEL DAVID | CAVATAR, LLC, CA | $299,999 | ZRG1 |
| 2017 | UV-emitting nanoparticles as novel radiation sensitizers targeting hypoxic cells1R41CA206645-01A1 | PURSCHKE, MARTINSQUILLANTE, MICHAEL R. | RADIATION MONITORING DEVICES, INC., MA | $299,992 | ZRG1 |
| 2017 | A practical and versatile high-resolution 3D dosimetry system for clinical use1R41CA217421-01A1 | ADAMOVICS, JOHN ARNEOLDHAM, MARK | HEURIS, INC., NJ | $299,962 | ZRG1 |
| 2017 | Raising the Therapeutic Index of Photodynamic Therapy with Targeted Nanosyringes1R41CA221420-01 | COOK, JASON | NANOHYBRIDS, INC., TX | $299,945 | ZRG1 |
| 2017 | Validation of a Diagnostic Test for Borrelia miyamotoi1R41AI134497-01 | LEDIZET, MICHEL | L2 DIAGNOSTICS, LLC, CT | $299,905 | ZRG1 |
| 2017 | Improved detection of bladder cancer recurrence using a biophysical biomarker1R41CA213584-01A1 | HENRY, MICHAEL D | SYNDERBIO, INC., IA | $299,860 | ZRG1 |
| 2017 | DRα1-MOG: A Novel Immunomodulatory Therapeutic for Stroke1R41NS103644-01 | ALKAYED, NABIL J | VIROGENOMICS BIODEVELOPMENT, INC., OR | $299,186 | ZRG1 |
| 2017 | Screening for the autoimmune component of multiple sclerosis1R41AI129571-01A1 | WAGNER, DAVID H. | OP-T-MUNE, INC., CO | $299,002 | ZRG1 |
| 2017 | Development of the first thermolytic to suppress shivering and seizure1R41HL135964-01A1 | DREW, KELLY L | BE COOL PHARMACEUTICS, LLC, AK | $298,871 | ZRG1 |
| 2017 | Targeting STT3A and STT3B to Block Flavivirus Replication1R41AI134531-01 | VAN ZANDT, MICHAEL CHRISTOPHER | NEW ENGLAND DISCOVERY PARTNERS, LLC, CT | $298,652 | ZRG1 |
| 2017 | Development of Pirenzepine for CIPN1R41CA213555-01A1 | MIZISIN, ANDREW | WINSANTOR, INC., CA | $298,550 | ZRG1 |
| 2017 | GRIM19 for head and neck cancer therapy1R41CA217438-01A1 | KALVAKOLANU, DHAN V. | GLYCOMANTRA, INC., MD | $298,517 | ZRG1 |
| 2017 | Probabilistic Modeling for Software-Guided Radiotherapy Patient Plan QA1R41CA217452-01A1 | KALET, ALAN M. | SUN NUCLEAR CORPORATION, FL | $297,681 | ZRG1 |
| 2017 | Developing a small peptide to control autoimmune inflammation in type 1 diabetes1R41AI131784-01 | WAGNER, DAVID H. | OP-T-MUNE, INC., CO | $297,387 | ZRG1 |
| 2017 | Novel Inhibitors of PSMB7 and PSMB10 for the Treatment of Multiple Myeloma1R41CA221494-01A1 | KISSELEV, ALEXEIPLETNEV, ALEXANDRE | INHIPROT, LLC, AL | $296,354 | ZRG1 |
| 2017 | Fc-folate Conjugate for the Treatment of Triple Negative Breast Cancer1R41CA213548-01A1 | SPEYER, CECILIA L | NEULINK, INC., MI | $295,747 | ZRG1 |
| 2017 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease1R42AG057329-01 | BURNS, LINDSAY HTHORNTON, GEORGE BENWANG, HOAU-YAN | CASSAVA SCIENCES, INC, TX | $295,343 | ZRG1 |
| 2017 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis1R41AI122666-01A1 · under PA-15-270 | ADHIKARI, RAJAN PHAKAMI, RAMIN M.NELSON, DANIEL C. | INTEGRATED BIOTHERAPEUTICS, INC., MD | $294,932 | ZRG1 |
| 2017 | Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity2R42DK104432-02 | JOHNSON, RICHARD JOSEPH | COLORADO RESEARCH PARTNERS, LLC, CO | $289,373 | ZRG1 |
| 2017 | Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents1R42HG009470-01A1 | ADAMS, NICHOLAS MDAWSON, ELLIOTT PAULHASELTON, FREDERICK R | BIOVENTURES, INC., TN | $287,251 | ZRG1 |
| 2017 | Large Scale Preparation of Natural Glycans1R41GM122139-01 · under PA-15-270 | SONG, XUEZHENG | NATGLYCAN, LLC, GA | $285,524 | ZRG1 |
| 2017 | Osteopontin-targeted therapy for primary CNS lymphoma1R41CA210669-01A1 | COPLAND, JOHN A.TUN, HAN W | MODULATION THERAPEUTICS, INC., WV | $283,986 | ZRG1 |
| 2017 | Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections1R41AI132102-01 | LIPKA, ELKE | TSRL, INC., MI | $283,958 | ZRG1 |
| 2017 | Development of a new small molecule therapeutic for the treatment of resistant breast cancer1R41CA210877-01A1 | LOUIE, STAN GEEPETASIS, NICOS A | VIOMEDIX, LLC, CA | $279,906 | ZRG1 |
| 2017 | Effects of LGM2605 on a Primate Model of Asthma1R41AI132012-01 | HACZKU, ANGELASIELECKI, THAIS MOTRIA | LIGNAMED, LLC, PA | $277,792 | ZRG1 |
| 2017 | Development of a POEGMA-Aptamer rapid onset anticoagulant that eliminates antigenicity to anti-PEG antibodies1R41HL139234-01 | CHILKOTI, ASHUTOSH | GATEWAY BIO, INC., NC | $277,130 | ZRG1 |
| 2017 | Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer1R41CA213715-01 · under PA-15-270 | LEOPOLD, JUDITH SWHITEHEAD, CHRISTOPHER EMIL | MEKANISTIC THERAPEUTICS, LLC, MI | $275,000 | ZRG1 |
| 2017 | Next Generation Regenerative Therapy with Pim-1 Enhanced Cardiac Progenitor Cells1R41HL137602-01 | SUSSMAN, MARK ALAN | CARDIOCREATE, INC., CA | $265,893 | ZRG1 |
| 2017 | Developing Multi-targeting Antiviral Agents Against Herpes Simplex 11R41AI134509-01 | WELLER, SANDRA K | QUERCUS MOLECULAR DESIGN, LLC, CT | $258,940 | ZRG1 |
| 2017 | Visually-driven disease variant analysis empowering real-time clinical research.1R41HG009629-01 | MARTH, GABOR TMILLER, CHASEWARD, ALISTAIR | FRAMESHIFT LABS, INC., MA | $256,443 | ZRG1 |
| 2017 | High throughput CRISPR/Cas9 cell line generation using the CellRaft Array platform1R41HG009467-01A1 | MARZLUFF, WILLIAM F. | CELL MICROSYSTEMS, INC., NC | $250,780 | ZRG1 |
| 2017 | Online Practitioner Training in Behavioral Intervention in Autism: Skill Training Using an Interactive Simulated Child1R41MH116534-01A1 · under PA-15-270 | SERNA, RICHARD W | PRAXIS, INC., MA | $250,387 | ZRG1 |
| 2017 | Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms1R41NS100184-01A1 | CHENEY, DARWIN LEROYGHANDEHARI, HAMID | THERATARGET, UT | $250,000 | ZRG1 |
| 2017 | Novel iobio analysis supporting genome scale data quality control.1R43HG009868-01 | MARTH, GABOR TMILLER, CHASEWARD, ALISTAIR | FRAMESHIFT LABS, INC., MA | $249,846 | ZRG1 |
| 2017 | Development and Validation of SafeClose Mesh Augmentation System for Hernia Prevention1R41GM123789-01A1 | FISCHER, JOHN PATRICK | PARADIGM SURGICAL, LLC, PA | $243,070 | ZRG1 |
| 2017 | A novel anti-gonorrhea immunotherapeutic1R41AI129106-01 · under PA-15-270 | RAM, SANJAYWYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $242,093 | ZRG1 |
| 2017 | Novel HDAC Inhibitors for Treatment of Hemoglobinopathies1R41HL136068-01 · under PA-15-270 | PERRINE, SUSAN PARKWILLIAMS, ROBERT MICHAEL | CETYA THERAPEUTICS, INC., CO | $241,742 | ZRG1 |
| 2017 | Developing a new therapeutic agent for retinal ciliopathies1R41EY027667-01 · under PA-15-270 | KATSANIS, NICHOLAS | RESCINDO THERAPEUTICS, INC., NC | $238,837 | ZRG1 |
| 2017 | Develop technology platform to transform the diagnosing, monitoring and treating of opioid use disorders1R41DA044905-01 | SCHMIDLE, PATRIK | CARI HEALTH, INC., CA | $235,848 | ZRG1 |
| 2017 | Next generation quantitative HCV drug resistance assay1R43DK112540-01A1 | WAGNER, RICHARDWANG, GARY P. | MEDOSOME BIOTEC, LLC, FL | $232,433 | ZRG1 |
| 2017 | Roboglasses® electronic travel aid with hands free obstacle avoidance for blind and vision impaired users1R41EY027623-01A1 | GIUDICE, NICHOLAS ASKIBA, JEFFRY | FAUXSEE INNOVATIONS, LLC, AR | $226,023 | ZRG1 |
| 2017 | A novel product for tendinopathy treatment1R41AG056246-01A1 | SUN, HUI BIN | NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER, NY | $225,042 | ZRG1 |
| 2017 | Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases1R41EY027219-01 · under PA-15-270 | COUSINS, SCOTT WILLIAM | EYEDESIS BIOSCIENCES, LLC, NC | $225,030 | ZRG1 |
| 2017 | Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients.1R41GM119871-01A1 · under PA-15-270 | DILLER, KENNETH R. | MERCURY BIOMED, LLC, OH | $225,000 | ZRG1 |
| 2017 | Oligonucleotide Inhibition for cardiac regeneration in Ischemia1R41HL134387-01A1 | BRAR, BHAWANJIT K | JAAN BIOTHERAPEUTICS, INC., CA | $225,000 | ZRG1 |
| 2017 | Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment1R41NS098918-01A1 | BOOHER, KEITHGUO, WEIHUANG, SHAOLING | ZYMO RESEARCH CORPORATION, CA | $225,000 | ZRG1 |
| 2017 | Hit-to-Lead optimization of small-molecule inhibitors of herpes simplex viruses1R41AI131739-01 | MORRISON, LYNDA A.ROGERS, BRUCE LEE | CASTERBRIDGE PHARMACEUTICALS, INC., MA | $225,000 | ZRG1 |
| 2017 | Personalized Neural Stem Cell Therapy for Cancer1R41TR001789-01A1 | NICHOLS, SUSAN | FALCON THERAPEUTICS, INC., NC | $225,000 | ZRG1 |
| 2017 | Novel methods to improve nuclease mediated homologous recombination1R41GM122181-01A1 | ZHANG, JIFENG | ATGC, INC., MI | $225,000 | ZRG1 |
| 2017 | Investigation of antibody-drug conjugates of a novel target1R41CA213479-01A1 | CUI, JIELIU, QINGYUN | WNTRIX, INC., TX | $225,000 | ZRG1 |
| 2017 | A Novel Scaffold to Promote Skin Regeneration1R41AR070681-01A1 | LEVINSON, HOWARD | XEQUEL BIO, INC., SC | $225,000 | ZRG1 |
| 2017 | Novel Reagents for Breast Tumor SPECT Imaging1R41CA217546-01 | LEVIN, MICHAEL DAVID | CAVATAR, LLC, CA | $225,000 | ZRG1 |
| 2017 | Developing a novel therapy for diabetic retinopathy1R41EY027665-01A1 | LI, WEITIAN, HONG | EVERGLADES BIOPHARMA, LLC, TX | $225,000 | ZRG1 |
| 2017 | E-training of Inmate Peer Caregivers for Enhancing Geriatric and End-of-life Care in Prisons1R41AG057239-01 | LOEB, SUSAN JAYNE | KLEIN BUENDEL, INC., CO | $225,000 | ZRG1 |
| 2017 | Neuro-Optical Diagnostic System for Macular Degeneration1R41AG057250-01 | SRIDHAR, SRINIVAS | NEUROFIELDZ, INC., MA | $225,000 | ZRG1 |
| 2017 | Skin Microbiome Editing with Fermentation Initiator1R41AR070676-01A1 | HUANG, CHUN-MING | SURFACE BIOADVANCES, INC., CA | $225,000 | ZRG1 |
| 2017 | Therapeutic game-based exercise during hemodialysis to improve balance and mobility1R41AG057743-01A1 | NAJAFI, BIJAN | BIOSENSICS, LLC, MA | $225,000 | ZRG1 |
| 2017 | Persistent-mode, Liquid-helium-free, Robust Bi2212 Magnets for MRI and >1GHz NMR1R43EB025109-01 | OTTO, ALEXANDER | SOLID MATERIAL SOLUTIONS, LLC, MA | $225,000 | ZRG1 |
| 2017 | Direct magnetic characterization of individual nanoparticles for optimized diagnostic imaging1R41MH115884-01 | ACOSTA, VICTOR MARCELJARMOLA, ANDREJS | ODMR TECHNOLOGIES, INC., CA | $225,000 | ZRG1 |
| 2017 | MISSION U: A Multimedia Training Tool for Treating Individuals with Co-occurring Mental Health and Substance Use Disorders1R41AA026751-01A1 | SMELSON, DAVID A | PRAXIS, INC., MA | $225,000 | ZRG1 |
| 2017 | Developing an automated yeast dissection system for aging research1R41AG058368-01 | DANG, WEIWEIJO, MYEONG CHAN | INNOVATIVE BIOCHIPS, LLC, TX | $225,000 | ZRG1 |
| 2017 | Noom Coach for Bariatric Surgery1R44DK116370-01 | HILDEBRANDT, THOMAS BMICHAELIDES, ANDREAS | NOOM, INC., NY | $225,000 | ZRG1 |
| 2017 | Drug-eluting Brachytherapy Implants for Chemo-radiation Therapy1R41CA224646-01 | SRIDHAR, SRINIVAS | THERANANO, LLC, MA | $225,000 | ZRG1 |
| 2017 | Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases1R43DK116450-01 | BLITZER, JEREMYSUMMERS, SCOTT A | POTRERO HILL THERAPEUTICS, INC., CA | $225,000 | ZRG1 |
| 2017 | Development of Environmental Health Education Games1R41ES027731-01A1 | JONES, PAULETTE THURLEY | MEADOWLARK SCIENCE AND EDUCATION, LLC, MT | $224,999 | ZRG1 |
| 2017 | Therapeutic disruption of Connexin43-mediated microtubule regulation to target glioblastoma cancer stem cells1R41CA217503-01 | LAMOUILLE, SAMY | ACOMHAL RESEARCH, INC., VA | $224,999 | ZRG1 |
| 2017 | Small-molecule therapy for metastatic prostate cancer1R41CA217491-01A1 | WU, DAQING | METCURE THERAPEUTICS, LLC, GA | $224,999 | ZRG1 |
| 2017 | Artificial neural networks for high performance, fully automated particle tracking analysis even at low signal-to-noise regimes1R41GM123897-01 | LAI, SAMUEL | AI TRACKING SOLUTIONS, LLC, NC | $224,997 | ZRG1 |
| 2017 | Preparation of site-specific antibody-drug conjugates by proximity-based sortase ligation1R41CA221374-01 | TSOURKAS, ANDREW | ALPHATHERA, INC., PA | $224,996 | ZRG1 |
| 2017 | An integrative multi-phenotype pipeline for drug evaluation, pharmacogenomics, and attribute prediction1R41TR001908-01 · under PA-15-270 | JAEGER, PHILIPP | PHENVOGEN, LLC, CA | $224,991 | ZRG1 |
| 2017 | Lead Compound Discovery from Engineered Analogs of Occidiofungin1R41AI131792-01 | SMITH, JAMES LEIF | SANO CHEMICALS, INC, TX | $224,939 | ZRG1 |
| 2017 | Polo-box PLK1 Inhibitors Target Tumors Resistant to ATP Competitive Compounds1R41CA213711-01A1 | MCINNES, CAMPBELL | PPI PHARMACEUTICALS, LLC, SC | $224,933 | ZRG1 |
| 2017 | Virtual-reality games to assess and habilitate auditory spatial awareness1R41DC016578-01 | ZOTKIN, DMITRY | VISISONICS CORPORATION, MD | $224,924 | ZRG1 |
| 2017 | A cloud-based software platform to enhance reproducibility, collaboration and translation of stem cell research1R41GM125489-01 | TUBON, THOMAS C | CELLARA, LLC, WI | $224,909 | ZRG1 |
| 2017 | Structure-based optimization of a novel pharmacological chaperone therapy for MPSIIIC1R41HD092110-01 | CHANG, GEOFFREY ASINGAMSETTY, SRIKANTH | PHOENIX NEST, INC., NY | $224,873 | ZRG1 |
| 2017 | Soluble E-NTPDase for sepsis1R41GM120838-01A1 · under PA-15-270 | HASKO, GEORGE | PURINE PHARMACEUTICALS, INC., NJ | $224,871 | ZRG1 |
| 2017 | Integrated tools for higher order structure determination by cross-link analysis1R41GM122169-01A1 | UEBERHEIDE, BEATRIX MAGDALENA | PROTEIN METRICS, LLC, CA | $224,870 | ZRG1 |
| 2017 | Hyperphosphorylated tau aggregation kit to identify tauopathy risk factor1R41AG057274-01 | BOCHAR, DANIEL | CAYMAN CHEMICAL COMPANY, INC., MI | $224,852 | ZRG1 |
| 2017 | A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation1R41GM117657-01A1 | RUPPERT, DAVID | DEEP BLUE MEDICAL ADVANCES, INC., NC | $224,837 | ZRG1 |
| 2017 | Mitochondrial Targeted Nano-antioxidants to Treat Alzheimer's Disease1R41AG055254-01A1 | PAUTLER, ROBIA G | ACELEROX, LLC, TX | $224,813 | ZRG1 |
| 2017 | Using Technology to Optimize Child Mental Health Care In Real World Settings1R41MH114716-01 | WHITESIDE, STEPHEN | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $224,744 | ZRG1 |
| 2017 | Develop a new cisplatin-based drug combination with reduced ototoxicity1R41DC016575-01 | BAO, JIANXIN | GATEWAY BIOTECHNOLOGY, INC., MO | $224,700 | ZRG1 |
| 2017 | Developing a Nutraceutical Product against Noise-Induce Hearing Loss1R41DC016842-01 | BAO, JIANXIN | GATEWAY BIOTECHNOLOGY, INC., MO | $224,700 | ZRG1 |
| 2017 | Development of a New Carbohydrate-based Anticoagulant Drug1R41HL139187-01 | LIU, JIAN | GLYCAN THERAPEUTICS CORPORATION, NC | $224,698 | ZRG1 |
| 2017 | Bioimpedance-based Intracranial Mapping for Monitoring Evolving TBI1R41NS100313-01 · under PA-15-270 | HALTER, RYAN JOSEPH | RYTEK MEDICAL, INC., NH | $224,609 | ZRG1 |
| 2017 | Targeting Synaptotagmin-2 to Prevent Airway Mucus Obstruction1R41HL136057-01 · under PA-15-270 | DICKEY, BURTON FVARADHACHARY, ATUL | EXOTECT, LLC, TX | $224,576 | ZRG1 |
| 2017 | Tools for site-specific antibody immobilization for immunoassays1R41EB023750-01 · under PA-15-270 | TSOURKAS, ANDREW | ALPHATHERA, INC., PA | $224,556 | ZRG1 |
| 2017 | SA-FasL-engineered human islets as a novel product for the treatment of type 1 diabetes1R41DK111314-01A1 | YOLCU, ESMA S | FASCURE THERAPEUTICS, LLC, KY | $224,529 | ZRG1 |
| 2017 | Lipid Enhanced Nano-Sensors (LENS) for lead and mercury detection in water1R41ES028643-01 | LENHERT, STEVEN | ZANSORS, LLC, VA | $224,528 | ZRG1 |
| 2017 | Microparticulate mucosal vaccine for triple-negative breast cancer1R41CA206652-01A1 · under PA-15-270 | CHIRIVA-INTERNATI, MAURIZIOMIRANDOLA, LEONARDO | KIROMIC, INC., TX | $224,522 | ZRG1 |
| 2017 | Biomimetic Wound Healing Devices to Close Diabetic Wounds1R41DK112416-01A1 | ENSLEY, BURT DEWITT | PROTEIN GENOMICS, INC., AZ | $224,503 | ZRG1 |
| 2017 | Online Training For Addressing Perinatal Depression1R41MH113381-01 | BYATT, NANCY | PRAXIS, INC., MA | $224,465 | ZRG1 |
| 2017 | TheraBracelet: The first and only wearable to instantly improve stroke hand function1R41HD090792-01A1 | SEO, NA JIN | THERABRACELET, INC., KY | $224,256 | ZRG1 |
| 2017 | Creation of animal models of mitochondrial DNA disease for translational research applications1R41GM125577-01 | RUIZ, JOSEPH C. | ENZERNA BIOSCIENCES, LLC, NC | $224,093 | ZRG1 |
| 2017 | Development of CaSR nutrient therapy for childhood diarrhea1R41HD092133-01 | CHENG, SAM X | MEDOSOME BIOTEC, LLC, FL | $223,899 | ZRG1 |
| 2017 | Telehealth Intervention for Improved Blood Pressure Control with Targeted Incentives: Using New Technologies and Insights From Behavioral Economics to Increase the Effectiveness of Behavioral Change1R41AG056184-01 | GNEEZY, URI | WELLTH, INC., NY | $223,743 | ZRG1 |
| 2017 | Automated Electrophysiology Assessment of Drug-induced Cardiotoxicity Based on Parallel, Noninvasive Nanoelectrode Array1R41EB022439-01A1 · under PA-15-270 | JIANG, XIN | CYION TECHNOLOGIES, LLC, CA | $223,028 | ZRG1 |
| 2017 | Biodegradable gold nanoparticles as contrast agents for CT1R41EB023169-01A1 | CORMODE, DAVID PETER | POLYAURUM, LLC, PA | $223,028 | ZRG1 |
| 2017 | Leveraging Health Information Technology to Improve School-Based Mental Health1R41MH112230-01A1 | FAGAN, COREY | MENTAL HEALTH DATA SERVICES, INC., WA | $222,784 | ZRG1 |
| 2017 | A Transparent Surgical Mask to Improve Patient/Caregiver Communication, Minimize Errors and Increase Patient Satisfaction1R41NR017124-01 | HAHNE, JEANNE | FACEVIEW MASK, LLC, OR | $222,317 | ZRG1 |
| 2017 | Preclinical Development of a Novel Small Molecule Drug for Sepsis1R41GM123858-01 | BRENNER, MAXWANG, HAICHAO | THERASOURCE, LLC, NY | $222,172 | ZRG1 |
| 2017 | Application of PPODA-QT for embolization of aneurysms1R41NS097069-01A1 · under PA-15-270 | BECKER, TIM | ANEUVAS TECHNOLOGIES, INC., AZ | $220,109 | ZRG1 |
| 2017 | AML-MutationCounter, a tool to detect residual and recurrent leukemia1R41CA213690-01 · under PA-15-270 | KAUFMANN, WILLIAM K. | ASYSTBIO LABORATORIES, LLC, NC | $220,087 | ZRG1 |
| 2017 | Therapeutic Mabs for Chronic Kidney Disease1R41DK112426-01 · under PA-15-270 | LUKACS, NICHOLAS W | OPSIDIO, LLC, PA | $217,446 | ZRG1 |
Showing the 200 most recent of 758 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.